Skip to content
    Clinical Trials

    Ribociclib With Endocrine Therapy Delays QOL Deterioration in HR+/HER2- Breast Cancer

    El Saghir et alThe oncologist

    Ribociclib With Endocrine Therapy Delays QOL Deterioration in HR+/HER2- Breast Cancer
    In the phase 2 randomized RIGHT Choice trial (NCT03839823), premenopausal and perimenopausal women with clinically aggressive hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer were randomized 1:1 to receive first-line ribociclib plus endocrine therapy (letrozole, anastrozole, or goserelin) or investigator's choice of combination chemotherapy. The parent trial previously reported a statistically significant progression-free survival benefit favoring ribociclib plus endocrine therapy over combination chemotherapy (21.8 vs 12.8 months; HR, 0.61; 95% CI: 0.43-0.87; P = .003), accompanied by lower rates of symptomatic adverse events.
    This prespecified analysis evaluated quality-of-life (QOL) outcomes using Kaplan-Meier analysis to calculate the median time to definitive deterioration (mTTDD) in Functional Assessment of Cancer Therapy-Breast (FACT-B) scores (defined as a decrease of ≥10%) as well as a composite mTTDD endpoint that included treatment discontinuation.
    Ribociclib plus endocrine therapy prolonged mTTDD compared to combination chemotherapy across FACT-B overall health status (HR, 0.72), trial outcome index (TOI; HR, 0.63), and nausea scores (HR, 0.59), whereas mTTDD for pain scores was similar between arms (HR, 1.05). In the composite mTTDD analysis accounting for treatment discontinuation, the ribociclib arm exhibited longer preservation across all evaluated domains: overall health status (HR, 0.68), TOI (HR, 0.65), pain (HR, 0.76), and nausea (HR, 0.62). The authors conclude that first-line ribociclib plus endocrine therapy translates into improved QOL compared with combination chemotherapy, reinforcing efficacy and safety findings that support cyclin-dependent kinase 4 and 6 inhibitors plus endocrine therapy as the preferred regimen for patients with clinically aggressive HR+/HER2- advanced breast cancer.

    Key Takeaways

    • First-line ribociclib plus endocrine therapy prolonged median time to definitive deterioration in FACT-B overall health status (HR, 0.72), trial outcome index (HR, 0.63), and nausea scores (HR, 0.59) compared with combination chemotherapy, while pain score deterioration was similar between arms (HR, 1.05).
    • When assessing a composite endpoint incorporating treatment discontinuation, ribociclib plus endocrine therapy extended median time to definitive deterioration across overall health status (HR, 0.68), trial outcome index (HR, 0.65), pain (HR, 0.76), and nausea (HR, 0.62).